Interferon-a (IFNa) signaling is essential for antiviral response via induction of IFN-stimulated genes (ISGs). Through a non-biased high-throughput RNAi screening of 711 known epigenetic modifiers in cellular models of IFNa-mediated inhibition of HBV replication, we identified methyltransferase SETD2 as a critical amplifier of IFNa-mediated antiviral immunity. Conditional knockout mice with hepatocyte-specific deletion of Setd2 exhibit enhanced HBV infection. Mechanistically, SETD2 directly mediates STAT1 methylation on lysine 525 via its methyltransferase activity, which reinforces IFN-activated STAT1 phosphorylation and antiviral cellular response. In addition, SETD2 selectively catalyzes the tri-methylation of H3K36 on promoters of some ISGs such as ISG15, leading to gene activation. Our study identifies STAT1 methylation on K525 catalyzed by the methyltransferase SETD2 as an essential signaling event for IFNa-dependent antiviral immunity and indicates potential of SETD2 in controlling viral infections.
INTRODUCTION
Type I interferons (IFNs) display potent antiviral activities via induction of IFN-stimulated genes (ISGs) through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway (Stark and Darnell, 2012; Sadler and Williams, 2008; Schneider et al., 2014) . Dysregulation of IFNa signaling has been closely associated with pathogenesis of various infectious and inflammatory disorders (McNab et al., 2015) . While the crucial role of IFNa-induced signaling pathways in host antiviral responses is well established, the mechanisms for the regulation of IFNa-triggered STAT signaling and ISGs expression remain to be fully elucidated.
In addition to phosphorylation and ubiquitination, which have been intensively investigated for their essential role in immunological signaling, other ''unconventional'' post-translational modification (PTM) such as methylation and acetylation are increasingly shown to be involved in appropriate control of immune and inflammatory responses (Biggar and Li, 2015; Cao, 2016; Chen and Dent, 2014; Liu et al., 2016; Mowen and David, 2014) . For example, mono-methylation of nuclear factor kB (NF-kB) subunit RelA by methyltransferase SET domain-containing protein 6 (SETD6) on K310 results in inhibition of NF-kBdriven inflammatory responses (Levy et al., 2011) ; di-methylation of STAT3 on K49 by methyltransferase enhancer of zeste homolog 2 (EZH2) is required for STAT3 activation and interleukin (IL)-6-induced gene transcription (Dasgupta et al., 2015) . STAT1 is the key transcription factor downstream of IFN signaling, which associates with STAT2 and IRF9 to form tri-complex or forms a homodimer to activate expression of a set of genes involved in cell proliferation, apoptosis, and immunological processes (Stark and Darnell, 2012) . The activation of STAT1 mainly depends on phosphorylation on tyrosine 701 catalyzed by kinase JAK1, which is crucial for IFNa-induced cellular antiviral signaling, however, the function of unconventional PTMs such as methylation in IFNa-triggered STAT activation as well as the crosstalk between different PTMs and the interaction dynamics in this process remain to be fully understood.
Epigenetic modifying factors and enzymes not only exert their ''classical'' role in controlling gene transcription by mediating covalent modifications of DNA and histone proteins, but also have the capacity to regulate cellular signaling and responses through modification of non-histone substrates (Mowen and David, 2014) . Several histone methyltransferases have been shown to regulate IFNa-mediated immune responses via control of expression of ISGs. For example, lysine methyltransferase, SET (Su [var] 3-9, E[z] and trithorax) domain bifurcated 2 (Setdb2), is induced by type I IFN in murine and human macrophages upon influenza A viral infection and catalyzes trimethylation within ISGs promoter regions to suppress ISGs transcription (Kroetz et al., 2015) . However, it is unclear whether epigenetic factors might directly modulate PTMs of IFNa-triggered signaling molecules independent of their ISG regulation activity.
Thus, it is urgent to systemically evaluate the roles of epigenetic molecules in IFNa-mediated antiviral activity.
Chronic hepatitis B caused by persistent hepatitis B virus (HBV) infection affects over 350 million people worldwide (Ott et al., 2012) . Currently, IFNa is used for the treatment of chronic hepatitis B in clinics. However, IFNa therapy has been shown to be effective in only a minority of HBV-infected patients (Scaglione and Lok, 2012) . The mechanism by which IFNa suppresses HBV infection is largely attributed to IFNa-triggered intrinsic immune signaling that induces the production of antiviral proteins (Lucifora et al., 2014; Yan et al., 2015) . Therefore, identifying new regulators of IFNa-mediated protective immunity against HBV infection is crucial for a comprehensive understanding of host anti-HBV immune responses and development of new therapeutic strategies to improve the efficacy of IFNa therapy.
Here, we performed a non-biased high-throughput RNAi screening of 711 known epigenetic modifiers for their potential roles in IFNa-mediated inhibition of HBV replication. We identified SET domain containing protein 2 (SETD2, also known as Huntingtin interacting protein B [HYPB] ), as a critical effector molecule that promotes IFNa-mediated cellular response against HBV replication. SETD2 is a histone methyltransferase catalyzing tri-methylation of H3K36 (Edmunds et al., 2008) and has been shown to participate in diverse biological processes including alternative splicing (Luco et al., 2010) , transcriptional elongation (Carvalho et al., 2013) , DNA repair (Carvalho et al., 2014; Li et al., 2013; Pfister et al., 2014) , and embryonic differentiation . In addition, mutations in SETD2 are associated with progression of several cancers, such as acute lymphoblastic leukemia and clear cell renal cell carcinoma (ccRCC) (Dalgliesh et al., 2010; Zhang et al., 2012; Zhu et al., 2014) . Up to now, the role of SETD2 in immunity and inflammation has not been reported, and the function of non-histone methylation by SETD2 remains unclear. In this study, we report a new role for SETD2 in promoting IFNa-induced antiviral immune response by directly methylating STAT1 on lysine 525 and catalyzing H3K36me3 on the promoters of some ISGs (such as ISG15) to activate gene transcription. Thus, SETD2 enhances host antiviral immunity by strengthening IFNa signaling both post-translationally and epigenetically.
RESULTS

RNAi Screening Identifies Epigenetic Candidates Regulating IFNa-Mediated Antiviral Response
To explore the epigenetic modifier landscape of antiviral immunity using IFNa-induced anti-HBV immune response as a model, we conducted a high-throughput small hairpin RNA (shRNA) screening in HBV-transfected HepG2.2.15 cells (Sells et al., 1987) using HBsAg secretion in the supernatant after IFNa treatment as the readout. The screening library consists of 1,422 unique shRNA-expressing lentivirus, leading to knockdown of 711 candidate epigenetic regulatory genes ( Figure 1A ; Table  S1 ). On the basis of fold changes in HBsAg secretion after shRNA transfection, 37 genes were selected as primary hits: silencing of 18 candidate genes, including PRMD7, NAT9, and AIP, enhanced HBsAg secretion by more than 2-fold, whereas silencing of the other 19 genes, including TGM3 and PHF8, inhibited HBsAg secretion ( Figure 1B ). Among these primary hits, AIP has been previously reported to interact with HBX, directly inhibiting HBsAg secretion (Kuzhandaivelu et al., 1996) , thereby confirming the validity of our screening system.
A secondary screen was performed to further validate the 37 primary hits. Three individual small interfering RNAs (siRNAs) were designed for each gene, and candidates were regarded as positive hits if transfection of at least two siRNAs caused significant changes in HBsAg secretion. A total of 21 positive hits were obtained from this secondary screen, including SETD2, ZCCHC4, TRIM28, and PHF8 ( Figure 1C ; Tables S2 and S3) . Of these 21 genes, our preliminary functional screening showed that HBsAg secretion and intracellular HBV DNA (both indicative of HBV replication) were significantly higher in SETD2-silenced HepG2.2.15 cells as compared to that in control cells in response to IFNa treatment ( Figure 1D ). HBV replication was also increased in SETD2-silenced HepG2 cells transiently transfected by pHBV1.3 plasmids ( Figure 1E ). The increase of HBV replication by SETD2 silencing was not due to changes in cell proliferation or IFNa-induced apoptosis (Figures S1A-S1C). Furthermore, by comparing the mRNA level of SETD2 in liver tissues from 20 HBV-positive (HBV + ) and 10 HBV-negative (HBV À ) patients with hepatocellular carcinoma (HCC) to normal liver tissues from six liver hemangioma patients (with no history of HBV infection), we found that the expression of SETD2 was significantly lower in HBV + samples than that in HBV À and healthy samples ( Figure 1F ).
Taken together, these data suggest that SETD2 plays a potent role in IFNa-mediated inhibition of HBV replication.
SETD2 in Hepatocytes Promotes IFNa-Mediated Inhibition of HBV Replication via Its SET Domain
We next focused on investigating the structure-function relationship of SETD2 in IFNa-induced antiviral immune response. SETD2 contains a SET domain with the adjacent associate with SET (AWS) and post-SET domain and a WW domain located in the C terminus (Sun et al., 2005) . The SET domain has been shown to be the catalytic methyltransferase domain and is considered as the signature motif of methyltransferase (Sun et al., 2005) . We constructed vectors encoding 1-945 amino acids (aa), 946-1738 aa (containing the SET domain), and 1739-2565 aa of SETD2 and named them fragment 1, 2, and 3, respectively ( Figure 2A) . Overexpression of the SETD2-fragment 2 (F2), but not SETD2-F1 or SETD2-F3, significantly promoted IFNa-mediated suppression of HBV replication (Figure 2A) , suggesting that SETD2 enhances anti-HBV activity of IFNa via its SET domain. To determine the in vivo effect of SETD2 on IFNa antiviral activity, we co-injected HBV-expressing plasmid (pHBV1.3) and SETD2-F2-expressing plasmid into C57BL/6 mice by hydrodynamic tail vein (HTV) injection that has been reported to be a mouse model of acute HBV infection (Yang et al., 2002) . Consistent with the in vitro results, overexpression of the SET domaincontaining SETD2-F2 potently reduced serum HBsAg titers ( Figure 2B ) and significantly decreased the densities of hepatitis B core antigen (HBcAg)-expressing hepatocytes in HBV-injected wild-type mice ( Figure 2C ). However, overexpression of SETD2-F2 did not inhibit HBV replication in mice deficient in IFNa 2.15 cells transfected with 1,422 targeting shRNAs followed by 1,000 U/mL IFNa treatment for 12 hr. Targeted genes that significantly increased or decreased HBsAg secretion are highlighted in red or green, respectively. (C) Fold changes of HBsAg secretion of HepG2.2.15 cells transfected with siRNAs for secondary validation followed by IFNa treatment as in (B) . Data are normalized to unstimulated HepG2.2.15 cells (dotted line). (D) qRT-PCR analysis of SETD2 expression (left), HBV relaxed circular DNA (rcDNA) (right), and ELISA of HBsAg secretion (middle) of HepG2.2.15 cells transfected with scrambled siRNA (si-NC) or siRNA specific for SETD2 (si-SETD2), followed by IFNa treatments as in (B) . (E) qRT-PCR analysis of SETD2 expression (left), HBV-DNA (right), and ELISA of HBsAg secretion (middle) of HepG2 cells co-transfected with pHBV1.3 plasmids and si-NC or si-SETD2, followed by IFNa treatment as in (B) . (F) qRT-PCR analysis of SETD2 expression in HBV-positive HCC tissues (n = 20), HBV negative HCC issues (n = 10), and normal liver tissues (n = 6). Data are shown as mean ± SD of three independent experiments. *p < 0.05, **p < 0.01. NS, not significant. See also Tables S1, S2, and S3. receptor (Ifnar1 À/À ) ( Figure 2C ). Furthermore, overexpression of SETD2-F2 significantly reduced the serum aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in HBV-injected wild-type mice, but not in HBV-injected Ifnar1 À/À mice ( Figure S1D ). Therefore, SETD2 promotes IFNa-mediated inhibition of HBV replication both in vitro and in vivo via its SET domain. SET domain proteins can be classified into seven subfamilies with different substrate selectivity depending on the sequences around SET domain. SETD2 and four other SET domain proteins including nuclear receptor binding SET domain protein (NSD1), NSD2, NSD3, and absent, small, or homeotic-like (Drosophila) (ASH1L), belong to the SET2 subfamily (Cheng et al., 2005) . Among all the SET2 subfamily members, SETD2 shares the highest homology with ASH1L. Therefore, we wondered whether SET domains of ASH1L may have similar effect in promoting IFNa activity as the SET domain of SETD2. Unlike SET domain-containing fragments of SETD2, overexpression of SET domain-containing fragments of Ash1l (1886-2958 aa) had no effect in IFNa-mediated inhibition of HBV either in vitro (Figure S1E) or in vivo ( Figure S1F ). These results indicate a unique role of SET domain-containing SETD2-F2 in promoting IFNa antiviral activity that is not shared by other SET domain-containing proteins. This is likely due to the special spatial configuration of SET domains in SETD2 consisting of three discrete b sheets arranged in a triangular shape, which significantly differs from other SET domains of other proteins (Yang et al., 2016) .
We then generated Setd2 conditional knockout mice with hepatocyte-specific deletion of Setd2 (Setd2 fl/fl Alb-cre + )
through homologous recombination and confirmed the deficiency of Setd2 expression in hepatocytes of Setd2 fl/fl Albcre + as compared to that of Setd2 fl/fl Alb-cre À control mice ( Figure 2D ). Notably, after HBV infection, Setd2 fl/fl Alb-cre + mice showed elevated HBsAg titers ( Figure 2E ), higher ALT and AST levels in serum ( Figure 2F ), as well as increased HBcAg expression in hepatocytes ( Figure 2G ) as compared to Setd2 Figure 3A ), STAT1 nuclear translocation ( Figure 3B ), and ISG15 mRNA expression ( Figure 3C ) were significantly reduced in SETD2-silenced HepG2 cells as compared to that in control HepG2 cells. Furthermore, in response to murine IFNa stimulation, the STAT1 phosphorylation and H3K36me3 levels ( Figure 3D ) and Isg15 mRNA expression ( Figure 3E) We then utilized CRISPR/Cas9 technology to knock out SETD2 in HepG2 cells, generating three SETD2-KO cell lines via targeting three distinct exons: exon1, exon3, and exon9 ( Figure S2A ). Each clonal cell line harbors a frameshift mutation in both SETD2 alleles ( Figures S2B-S2D ), resulting in loss of SETD2 expression ( Figure S2E ) and decreased total H3K36me3 levels ( Figure 3F ). All three SETD2-KO HepG2 cell lines showed impaired phosphorylation of STAT1 induced by IFNa as compared to control HepG2 cells (Figures 3G and S2F) . No significant difference in the expression of IFNAR1/R2 or STAT1 upstream signaling molecules such as tyrosine kinases Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) were observed in IFNa-treated SETD2-KO HepG2 cells (data not shown). Through RNA sequencing (RNA-seq) analysis, we found that the expression of a set of ISGs was lower in SETD2-KO cells than that in HepG2 WT cells in response to IFNa stimulation ( Figure 3H ). qRT-PCR analysis confirmed reduced expression of two ISGs, including ISG15 and MX2 after IFNa stimulation in SETD2-KO cells ( Figure 3I ). In response to stimuli with other subtypes of IFNs including IFNb, IFNg, and IFNl, the levels of STAT1 phosphorylation, H3K36me3 (Figure S3A) , and ISG15 mRNA expression ( Figure S3B ) were also reduced in SETD2-KO cells than that in HepG2 WT cells. Therefore, SETD2 enhances STAT1 phosphorylation and ISG expression triggered by all types of IFNs.
We next performed rescue experiments using SETD2 or STAT1 overexpression plasmids to further elucidate SETD2-mediated regulation of IFN signaling. Overexpression of the SET domain-containing SETD2-F2, but not other fragments (SETD2-F1 and SETD2-F3), in SETD2-KO cells upregulated IFNa-induced ISG15 expression ( Figure 3J ) and H3K36 methyltransferase activity ( Figure 3K ). We also generated STAT1-knockout (STAT1-KO) cell lines using CRISPR/Cas9 targeting exon6 of STAT1 and confirmed the loss of STAT1 protein in STAT1-KO cells ( Figure S3C ). We then generated an active mutation of STAT1 with substitution of cysteine for alanine at positions 656 and 658 (STAT1-CC) that constantly enhanced (E) IFN-induced expression of ISG15 and MX2 and STAT1 phosphorylation in STAT1-KO cells (Zhang et al., 2015b) (Figures S3D and S3E) . Overexpression of STAT1-CC could significantly enhance IFNa-induced STAT1 phosphorylation ( Figure 3L ) and upregulate IFNa-induced ISG15 and MX2 mRNA expression ( Figure 3M ) in both HepG2 cells and SETD2-KO cells. These results further indicated that SETD2 enhances IFNa-induced ISG expression by promoting STAT1 activation via SET domain-containing fragment. We then analyzed whether SETD2 could regulate innate defense against different types of virus infection. Upon infection with DNA virus herpes simplex virus (HSV), vaccinia virus (VACV), and also RNA virus VSV, the viral titers and replications in SETD2-KO HepG2 cells, in the absence of IFNa pretreatment, remained almost unchanged compared to that in control HepG2 cells. By contrast, viral titers and replications in SETD2-KO HepG2 cells, in the presence of IFNa pretreatment, were increased at least ten times more than in control cells ( Figures  3N and S3F ), indicating the important role of SETD2 in IFNa-mediated antiviral effect. Collectively, SETD2 is critical for optimal activation of IFNa-dependent STAT1 activation and ISG expression and for efficient innate defense against different types of virus.
SETD2 Directly Induces Mono-methylation of STAT1 via Methyltransferase Activity
The above data suggest that SETD2 enhances STAT1 phosphorylation and nuclear translocation in response to IFNa. Because several histone methyltransferases have been shown to mediate methylation of non-histones and thus affect protein function and signaling transduction (Dasgupta et al., 2015; Levy et al., 2011) , we asked whether SETD2 mediates methylation of signaling molecules such as STAT1 to affect its activity. Interestingly, IFNa stimulation induced mono-methylation of STAT1 (Figure 4A) . Silencing of SETD2 reduced IFNa-induced STAT1 mono-methylation in HepG2 cells ( Figure 4B ), whereas overexpression of the SET domain containing SETD2-F2 led to increased mono-methylation and phosphorylation of STAT1 than SETD2-F3 ( Figure 4C ).
It has been reported that mutation of arginine (R) 196 and cysteine (C) 202 in the SET domain of yeast SET2 abrogates methyltransferase function (Rea et al., 2000) . Using sequence homology comparison, we found that these two residues are evolutionarily conserved, and R1625 and C1631 in human are homologous to R196 and C202 in yeast ( Figure 4D ). We transfected the SET domain-containing SETD2-F2 with R1625G or C1631A point mutations into SETD2-KO HepG2 cells and found that the R1625G SETD2 fragment abolished H3K36me3 methyltransferase activity, whereas C1631A did not affect H3K36me3 levels ( Figures 4D and 4E ). While SETD2-F2 enhanced monomethylation and phosphorylation of STAT1, the methyltransferase-dead SETD2-F2 (R1625G) lost the ability to enhance STAT1 mono-methylation and phosphorylation ( Figure 4F ). In addition, co-immunoprecipitation experiments in HEK293T cells suggested that SETD2-F2, but not other fragments, interacted with STAT1 ( Figure 4G ). Although the expression of SETD2 itself was not upregulated by IFNa, the interaction between SETD2-F2 and STAT1 was dependent on IFNa stimulation ( Figure 4H ). These data suggest SETD2 interacts with STAT1 upon IFNa stimulation to induce mono-methylation of STAT1 via methyltransferase activity.
We also constructed a group of glutathione S-transferase (GST)-fusion proteins respecting different SETD2 truncations (SETD2 T1-T6) and 63 his-fusion full-length STAT1 and detected a direct and specific interaction between SETD2-T3 and STAT1 proteins ( Figure 4I ). We then further divided SETD2 T3 and T4 into N-terminal and C-terminal (T3N, T3C, T4N, and T4C), respectively, to determine the exact region in SETD2 that interacts with STAT1 ( Figure 4J ). Pull-down assay demonstrated that SETD2 T3C and T4N, both containing SET domain, bind to STAT1 ( Figure 4J ), indicating SET domain was sufficient for interaction with STAT1. However, we did not observe the interaction between STAT1 and SETD2 T4 that also contains SET domain. This might be due to the low expression efficiency of SETD2 T4 protein ( Figure 4I ). Taken together, these results suggest that SETD2 interacts with STAT1 to mediate its methylation via the methyltransferase activity in response to IFNa stimulation. (C) qRT-PCR analysis of ISG15 expression in HepG2 cells transfected and stimulated as in (A) . ( 
Methylation of Lysine 525 of STAT1 Is Necessary for Its Phosphorylation and Transcriptional Activity
The above data suggest that SETD2 directly interacts with STAT1 and mediates its methylation in response to IFNa stimulation. To confirm the direct interaction between SETD2 and STAT1 and subsequent methylation of STAT1, we performed mass spectrometry (MS) analysis and systemically identified potentially methylated lysine residues of STAT1 induced by IFNa ( Figure S4A ). A total of seven mono-methylated lysine residues (K114, K175, K296, K366, K525, K637, and K665) were identified ( Figures 5A, 5B , and S4B). However, di-and tri-methylation on lysine residues of STAT1 were not detected in our MS analysis.
To further investigate the effect of methylation on STAT1 activity, we constructed STAT1 mutations with all the MS-identified methylated lysine residues (K) replaced with alanine (A), as well as a double-site mutation on K636/K637. Out of the eight lysine to alanine mutants tested, only the overexpression of STAT1 K525A led to significantly reduced IFNa-induced STAT1 phosphorylation on tyrosine 701 ( Figure 5C ) and nuclear translocation ( Figure 5D ) as well as decreased expression of ISGs including ISG15, IFIT-1, and MX2 ( Figure 5E ) in STAT1-KO cells. The interaction between JAK1 and STAT1 by IFNa stimulation was reduced by STAT1-K525A mutation in both HepG2 cells and human primary macrophages derived from CD14 + human peripheral blood monocytes cultured in M-CSF ( Figures 5F and S5A) . Moreover, electrophoretic mobility shift assay (EMSA) with biotin-labeled single ISRE or GAS probes showed that K525A-mutated STAT1 showed significantly less binding with ISRE and GAS elements ( Figure 5G ). Unexpectedly, K525A mutation did not influence homo-dimerization of STAT1 ( Figure S5B ), hetero-dimerization of STAT1 and STAT2 ( Figure S5C ), nor the interaction between STAT1 and IRF9 ( Figure S5D ). It was shown that both phosphorylated and unphosphorylated STAT1 can dimerize or interact with STAT2 and IRF9 (Cheon and Stark, 2009; Sung et al., 2015) , which may partially explain why K525 mutation inhibited STAT1 phosphorylation, but did not affect STAT1 dimerization and STAT2 or IRF9 interaction. It will be intriguing to further clarify the detailed mechanisms involved in the differential effect of STAT1 K525me1 in its molecular interactions. Collectively, these data demonstrate that K525 of STAT1, which is a critical methylation lysine residue on STAT1, is required for IFNa-induced STAT1 interaction with JAK1 and for the phosphorylation, nuclear translocation, and DNA binding activity of STAT1 as well as for the subsequent expression of ISGs.
SETD2 Directly Mediates Mono-Methylation of STAT1 on K525
We next sought to determine whether SETD2 is necessary and sufficient for STAT1 K525me1. While mutation of K525 decreased the level of mono-methylation of STAT1 upon IFNa stimulation ( Figure 6A ), SETD2-F2 overexpression significantly enhanced STAT1 mono-methylation in STAT1-KO cells rescued with overexpression of STAT1 but not in STAT1-KO cells rescued with overexpression of STAT1 K525A mutation ( Figure 6B ). To further validate these data in vivo, we induced lentivirusmediated stable expression of STAT1-WT (WT-Re) or STAT1-K525A (K525A-Re) in STAT1-KO cells. In line with the reduced STAT1 activation, ISG expression and viral resistance in SETD2-KO cells ( Figures 3G, 3I, and 3N ), STAT1-K525A-Re cells also had reduced STAT1 phosphorylation ( Figure S6A ), ISGs expression ( Figure S6B ), and impaired resistance to viral infection ( Figure S6C ) as compared to that in WT-Re cells in response to IFNa stimulation. Furthermore, we generated a specific polyclonal antibody against a STAT1 K525me1 peptide. Dot blot analysis demonstrated minimal cross-reactivity of the polyclonal antibody with un-methylated K525 containing peptide (Figure S6D ). Western blot with the specific K525me1 antibody showed that methylation of this lysine residue of STAT1 could be induced by IFNa or IFNg, which was significantly decreased in K525A-Re cells as compared to that in WT-Re cells ( Figure 6C and S6E). Importantly, silencing of SETD2 significantly reduced K525me1 of STAT1 in HepG2 cells induced by IFNa ( Figure 6D ). Because SETD2 not only catalyzes trimethylation of H3K36 but also mono-and di-methylation of H3K36 (Yuan et al., 2009 ), we next investigated whether SETD2 could directly methylate STAT1. In the in vitro methylation assay, we used purified STAT1 or histone as the substrate, S-adenosyl-L-methionine (SAM) as the methyl group donor, and purified GST-tagged SETD2 T4N (mainly SET domain) as the enzyme. We found that SETD2 could indeed directly catalyze both K525me1 of STAT1 and H3K36me3 of histones ( Figures 6E and S6F ). In line with the importance of K525 of STAT1 for its interaction with JAK1, SETD2-KO cells also showed reduced interactions between endogenous STAT1 and JAK1, but intact STAT1-STAT2 or STAT-IRF9 interactions in response to IFNa or IFNb stimulation ( Figures 6F and 6G ). Taken together, these results indicate that methyltransferase SETD2 directly mediates mono-methylation of K525 of STAT1, which is an important PTM enhancing STAT1 activation and expression of ISGs. (C) IB analysis of pSTAT1 and total STAT1 in whole-cell lysates of STAT1-KO HepG2 cells transfected with wild-type STAT1 (STAT1-WT) or point mutated STAT1 expression plasmids, followed by 1,000 U/mL IFNa treatment for 6 hr. (D) IB analysis of pSTAT1 and total STAT1 in nuclear and cytoplasmic (cyto) extracts of STAT1-KO cells transfected with STAT1-WT or STAT1-K525A expression plasmids and stimulated as in (C) . (E) qRT-PCR analysis of ISG15, IFIT-1, and MX2 expression in STAT1-KO cells treated as in (C) . (F) IB analysis of immunoprecipitates of STAT1-KO HepG2 cells co-transfected with myc-tagged JAK1 and flag-tagged STAT1-WT or STAT1-K525A expression plasmids followed by IFNa treatment for 30 min. (G) EMSA of whole-cell lysates from STAT1-KO cells transfected as in (C) and treated with IFNa for indicated time. 13 ISRE motif and 13 GAS motif were biotinlabeled. Data are representative photographs of three independent experiments with similar results or shown as mean ± SD of three independent experiments (E). *p < 0.05, **p < 0.01, ***p < 0.001. See also Figures S4 and S5 .
SETD2 Selectively Promotes Expression of ISGs by H3K36me3 Modification
Although the IFNa-induced expression of a set of ISGs such as ISG15 and MX2 was reduced by SETD2 silencing (Figure 3I ), expression of other ISGs such as RIG-I was not affected (data not shown). Thus, SETD2 might regulate expression of ISGs in a gene-selective manner. We therefore performed unbiased transcriptome profiling with RNA-seq in SETD2-KO cells, STAT1-K525A-Re cells, STAT1-KO cells, as well as control HepG2 cells stimulated with IFNa for 6 hr ( Figure 7A ). Out of the 222 genes that are induced in control HepG2 cells after IFNa stimulation, the induction of 89, 128, and 180 genes was significantly lower in SETD2-KO cells, STAT1-K525A-Re cells, and STAT1-KO cells as compared to that in control HepG2 cells, respectively ( Figure 7B ). A gene ontology (GO) enrichment analysis demonstrated that the genes with lower expression in SETD2-KO cells and STAT1-K525A-Re cells could be categorized into defense response to virus or type I IFN pathwayrelated genes ( Figure 7C ). Among the 180 genes differentially induced in IFNa-stimulated STAT1-KO cells, 40% of them were also lower in IFNa-stimulated SETD2-KO cells, indicating that SETD2 promotes the expression of a set of STAT1-dependent ISG ( Figure 7D ). In addition, 75 genes showed lower expression both in SETD2-KO cells and STAT1-K525A-Re cells after IFNa stimulation, including those ISGs with potent antiviral functions, such as ISG15, ISG20, MX2, etc. ( Figures  7D and 7E) . The data further confirmed that SETD2-mediated ISGs regulation is to a large extent dependent on its effect in mediating STAT1 K525 mono-methylation.
Given that SETD2 is the only methyltransferase reported to be required for H3K36me3, a marker of transcriptional activation, we hypothesized that expression of some ISGs are dependent on H3K36me3 modification. By chromatin immunoprecipitation (ChIP)-qPCR assay using anti-H3K36me3 antibody, we found the amount of H3K36me3 in the promoter region of ISG15 and IP-10 and the gene body region of IFIT-1 was increased after IFNa treatment, whereas the amount of H3K36me3 in the promoter region of RIG-I remained unchanged. Furthermore, IFNa-induced accumulation of H3K36me3 in the ISG15 and IP-10 promoter region and IFIT-1 gene body region was significantly abolished in both SETD2-silenced and SETD2-KO HepG2 cells, indicating that SETD2 selectively promotes H3K36me3 in some genes including ISG15, IP-10, and IFIT-1 gene loci in response to IFNa ( Figures 7F, 7G , S7A, and S7B). Taken together, these data indicate that coordinating with mono-methylating STAT1 on K525 to enhance IFN signaling, SETD2 selectively catalyzes H3K36me3 modification of a set of ISGs gene loci to promote their expression.
DISCUSSION
Identifying how type I IFN-mediated immune response against viruses is activated and tightly regulated has been one of most challenging issues in the field of antiviral innate immunity (Fusco et al., 2013; Pulloor et al., 2014; Schoggins et al., 2011; Zhao et al., 2012) . In this study, we performed a high throughput screening of epigenetic modifiers by lentivirus-mediated RNAi to search for the epigenetic factors that are involved in IFNa-mediated antiviral response. This approach yielded the discovery and successfully identified that the methyltransferase SETD2 is a critical effector molecule that increases IFNa-induced STAT1 activation by directly methylating STAT1, opening new avenues for study of the pathogenesis of various immune disorders and outlining potential strategies for disease prevention and treatment. Our screening system can also be broadly applied in a wide variety of biological and immunological investigations, such as cellular responses to inflammatory or cytokine stimuli.
The role of unconventional PTMs, such as acetylation, SUMOylation in regulation of STAT1 activation, and IFN signaling, is attracting more and more attention. It was shown that STAT1 acetylation induced binding of protein tyrosine phosphatase (TCP45) that catalyzes dephosphorylation and inactivation of STAT1 (Ginter et al., 2012) . SUMO conjugation of STAT1 is associated with hypo-responsiveness to IFNg (Begitt et al., 2011) . Methylation on Arg31 of STAT1 by protein arginine methyltransferase 1 (PRMT1) is required for IFNa/b-induced gene transcription (Mowen et al., 2001) . Here, we identified monomethylation of STAT1 on lysine 525 as an important PTM that is critical for phosphorylation, nuclear translocation, and DNAbinding activity of STAT1, eventually contributing to IFNa-induced antiviral response. The core region of STAT1 contains four tandem structural domains: coil-coiled domain, DNA binding domain, linker domain, and SH2 domain, and each of the four domains is fused to the adjacent ones by the formation of a contiguous hydrophobic core. Furthermore, interaction between SH2 domain (containing Y701 site for phosphorylation) and the elements of linker domain (containing K525 for methylation) was proposed to be essential for buttressing the phosphate-binding loop of the STAT1 SH2 domain (Chen et al., 1998) . Therefore, we propose that SETD2-mediated methylation of STAT1 K525 may promote the formation of phosphatebinding loop in SH2 domain and then facilitate STAT1 Y701 phosphorylation.
SETD2 is responsible for H3K36me3 and has been recently shown to tri-methylate a-tubulin on K40, which is required for mitosis and genomic stability (Park et al., 2016) . Here, we discover an important role of SETD2 in promoting IFNa-initiated antiviral immunity via directly mediating K525me1 of STAT1. It will be intriguing to further investigate the crosstalk between histone modification and non-histone PTMs by SETD2 in the context of immunity and inflammation. Interestingly, there was a modest upregulation of HBsAg after overexpression of F3 fragment of SETD2 containing WW domain, indicating a potentially negative regulatory role of the C-terminal fragment of SETD2 in IFNa activity. One possible explanation is that WW domain may have a potential role in affecting antiviral immunity because WW domain of NEDD4 was shown to interact with IFITM3 to inhibit antiviral function (Chesarino et al., 2015) .
According to the transcriptional profiling analysis, SETD2 enhances the expression of a set of STAT1-dependent ISG expression. The induction of ISG is a dynamic cellular process significantly dependent on stimulation magnitude, frequency, and time course (Mostafavi et al., 2016) . Although SETD2-mediated K525me1 of STAT1 is critical of STAT1 phosphorylation and transcriptional activity, the downstream effect in global ISG expression of SETD2 may be dynamically regulated by other factors such as transcriptional factors, epigenetic enzymes, and chromatin remodelers in the nucleus. Notably, the ISGs dependent on SETD2 and STAT1-K525 methylation include those ones that have been shown to be critical for antiviral responses such as ISG15, ISG20, MX2, etc. Therefore, SETD2-mediated STAT1-K525me1 is essential for the expression of a set of ISGs, consequently contributing to cellular defense against viral infection. It merits further investigation to clarify the mechanism underlying the gene selectivity of SETD2-mediated regulation of ISG expression.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Xuetao Cao (caoxt@immunol.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Ifnar1 deficient (Ifnar1 À/À ) C57BL/6 mice (B6.129S2-Ifnar1
tm1Agt
) and Alb-cre mice (B6.Cg-Tg(Alb-cre)21Mgn/J) were obtained from The Jackson Laboratory. C57BL/6 mice (6-8 weeks of age) were obtained from the Shanghai Laboratory Animal Center, Chinese Academy of Science. Setd2 fl/fl mice were generated by Bacterial Artificial Chromosomes (BAC) recombineering technology. Shortly, by homologous recombination, two floxp sequences were inserted and located at the upstream and downstream intron of the 3rd exon of Setd2 gene in mice embryonic stem cell (ES) clones, respectively. Then ES clones with floxp were injected into C57BL/6 blastocysts to generate high-percentage chimeras. Setd2-floxed allele (Setd2 fl/fl ) crossing with Alb-cre + mice generated Setd2 conditional knockout mice (Setd2 fl/fl Alb-cre + ). All mice were maintained in SPF conditions. All animal experiments were performed according to the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of Second Military Medical University, Shanghai.
Clinical Specimens
The liver tissue samples of HCC and adjacent tissues were obtained from 30 HCC patients who underwent open surgery in 2015 at Shanghai Eastern Hepatobiliary Surgery Hospital. Normal human liver tissues were obtained from distal normal liver tissue of 6 liver hemangioma patients (with no history of HBV infection) from Shanghai Changzheng Hospital. Liver tissue samples were immediately snap frozen in liquid nitrogen and then stored at À80 C as described previously (Hou et al., 2014) . Donors were all male patients on average 55 years old (range from 35-70 years old). All samples were collected with written informed consent from the patients and were approved by the institutional review board at each study center.
Culture and Maintenance of Cells HEK293T and BHK-21 cell lines were from American Type Culture Collection; HepG2.2.15 cell line was from Cell Bank of the Chinese Academy of Sciences; Hepatocellular carcinoma (HCC) cell lines HepG2 and BEL-7402 were obtained as reported previously (Hou et al., 2014) . Primary mouse hepatocytes were isolated from mouse liver tissue digested by IV Collagenase. Above cell lines were maintained in endotoxin-free DMEM (PAA laboratory), supplemented with 10% FCS (GIBCO), 5 mg/ml penicillin (GIBCO) and 10 mg/ml streptomycin (GIBCO), at 37 C with 5% CO 2 . Human peripheral blood mononuclear cells (PBMNCs) were collected and purified by Ficoll-Paque PLUS (GE healthcare) density gradient centrifugation. Human CD14+ monocytes were then purified from human PBMCs by CD14 + Cell Isolation Kit (Miltenyi Biotec, CA, USA) and then cultured for 6 days in RPMI-1640 supplemented with 10% FCS (GIBCO) and 10 ng/ml hM-CSF (Perprotech) for generation of human macrophages. 
METHOD DETAILS
Generation and Validation of SETD2/STAT1 Knockout Cells Three gRNAs were designed to knock out SETD2 (5 0 -CCG CAG CCG CCT CCG AAG AT À3 0 (to target SETD2 exon1), 5 0 -AAT GAA CTG GGA TTC CGA CG À3 0 (to SETD2 exon3) and 5 0 -TGC GGA TCA GCC AAT TGC CG À3 0 (to SETD2 exon9)). One sgRNA was picked to knock out STAT1 (5 0 -AGG TCA TGA AAA CGG ATG G À3 0 ). To validate and pick out the knockout cell colonies, genomic DNA was extracted from the parental and knockout HepG2 cells and amplified with primers located $300 bp from the target site. PCR products were Sanger sequenced, and sequences were aligned using the BioEdit ClustalW multiple sequence alignment tool.
High Throughput Screening A lentivirus library of 1422 unique shRNAs targeting 711 human epigenetic modifiers (3D-HTS Technology) was used in the high throughput screening (Table S1 ). In the primary screening, 1 3 10 3 HepG2.2.15 cells were seeded in each well of 96-well plates and infected by the arrayed one single and distinct lentivirus. 72 hr after infection, cells were treated with 1,000 U/ml human IFNa-2b (Pestka Biomedical Laboratories) for another 12 hr. The supernatants were harvested and assessed for the secreted HBsAg concentration by ELISA. The fold changes of HBsAg secretion of lentivirus-transfected HepG2.2.15 cells were normalized to the scrambled shRNA. In the secondary screening, three individual siRNAs were designed and synthesized for each candidate, transfected into the seeded HepG2.215 cells, and treated as in primary screen. Genes were regarded as positive hits if they were scored by at least two siRNAs.
Generation of SETD2-KO Cells or STAT1-KO Cells
The SETD2 or STAT1 knockout (KO) cells were constructed using the CRISPR/Cas9 gene-editing system. The CRISPR plasmid, a kind gift from Dr. Cong Huai (Fudan University), contains expression cassettes of Cas9, chimeric gRNA and CopGFP. The target sequences of gRNAs were designed using the MIT online tool (http://crispr.mit.edu/), and are listed in STAR Methods. The CRISPR plasmids were transfected into HepG2 cells using JET-PEI (Polyplus-transfection), and single-cell colonies of GFP-positive cells were picked and validated at DNA and protein expression level by genomic DNA sequencing and western blot.
Generation of the Mouse Model of HBV Acute Infection
The HBV acute infection mouse model was generated by HTV injection of the plasmids pHBV1.3, which contain a replication-competent 1.3-fold over-length type C HBV genome. In brief, 20 mg of pHBV 1.3 plasmids solution were diluted into 1.5 mL saline (final volume), and were injected into tail vein of mice within 5-7 s for maximum liver absorption (Yang et al., 2002) . The control group received 1.5 mL saline without any plasmids. Sera were harvested at indicated time after injection from the whole blood of mice. The concentration of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and HBsAg level were measured by ELISA.
Mass Spectrometry (MS) Analysis of Lysine Methylation
MS analysis was performed as described . In brief, 1 3 10 8 HepG2 cells were treated with 1,000 U/ml IFNa for 6 hr, and then lysed in 6 mL M-PER Protein Extraction buffer. Extracts was subjected to immunoprecipitation with 10 mg antibody specifically recognizing STAT1 (Cell Signaling Technology) or IgG overnight at 4 C. Then pre-blocked 100 mL protein A/G agarose beads with 0.1% BSA were added to incubation for 2 hr. Beads were washed three times with NETN (100 mM NaCl, 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 0.05% (v/v) NP-40), then boiled and loaded to SDS-PAGE. After Coomassie Blue staining, the STAT1 specific bands compared to IgG control were cut and then analyzed in reverse-phase nanospray liquid chromatography-tandem mass spectrometry. The spectra from tandem mass spectrometry were automatically used for searching against the non-redundant International Protein Index mouse protein database (version 3.72) with the Bioworks browser (rev.3.1).
RNA Interference siRNAs were transfected using INTERFERin (Polyplus-transfection) at a final concentration of 20 nM following manufacturer's instructions.
Cell Growth Assay
Cell growth of HCC cell lines was determined using Cell Counting Kit-8 (CCK8) (Dojindo) according to manufacturer's protocol. Briefly, 1 3 10 3 cells were seeded into 96-well plates and transfected with siRNAs; 36 hr after transfection, fresh culture medium with 10 mL CCK8 solution was added and incubated for 1 hr at 37 C. The absorbance was measured at 450 nm.
RNA Isolation and qRT-PCR Assay
Total RNA was extracted from cells and frozen human liver tissues using TRIzol reagent (Invitrogen) according to manufacturer's protocol. qRT-PCR analysis was performed using LightCycler (Roche) and SYBR RT-PCR kit (Takara) as described previously (Liu et al., 2014a) . Data were normalized to GAPDH expression.
Viral Infection and TCID50 Assay
Cells were infected with VSV, HSV and VACV (1 MOI) for 24 hr. Then the supernatants collected for TCID 50 assay as described previously (Chen et al., 2013) .
Flow Cytometry
Apoptosis analysis was performed by flow cytometry as previously described (Hou et al., 2014) . Briefly, cells were treated with 1,000 U/ml human IFNa-2b for the indicated time, harvested, washed, and stained with Annexin V-APC and propidium iodide (PI) at room temperature for 15 min. Resuspended cells were subjected to FACS analysis using a LSR II and data were analyzed by FACSDiva software (BD Biosciences).
ELISA Secreted HBsAg in cell culture supernatants or sera from acute HBV mouse model were analyzed using human HBsAg ELISA kit (Shanghai Kehua Bio-engineering Co., Ltd) following the manufacturer's instructions. Levels of alanine transaminase (ALT) and aspartate transaminase (AST) in serum of mice were detected using ELISA kits (Rongsheng) following the manufacturer's protocol.
Immunoprecipitation and Western Blot
Cells were harvested and lysed using M-PER Protein Extraction Reagent (Pierce), nuclear extracts from cells were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher) following manufacturer's instructions supplemented with protease inhibitor cocktail (Calbiochem). Protein concentrations were determined with bicinchoninic acid assay (Pierce). Equalized extracts were used for immunoprecipitation and immunoblot analysis, which has been described previously (Chen et al., 2013) .
Electrophoretic Mobility-Shift Assay
Wild-type and K525A STAT1 plasmid-transfected cells were stimulated by IFNa. These cells were lysed and then incubated with biotin-labeled ISRE (Forward: 5 0 -GGG AAA GGG AAA CCG AAA CTG A-3 0 , reverse: 5 0 -TTC AGT TTC GGT TTC CCT TTC CC-3 0 ) and GAS (Forward: 5 0 -CGA CAT TTC CCG TAA ATC TG-3 0 , reverse: 5 0 -CAG ATT TAC GGG AAA TGT CG-3 0 ) probe (Synthesized by Sangon Biotechology) before being separated by electrophoresis and visualized by autoradiography.
Expression and Purification of GST or 6 3 His Fusion Proteins and Histone Proteins Extraction
The sequence encoding STAT1 was cloned into a pET-28a expression vector between the NheI and NotI sites, followed by a 6 3 his tag. Sequences encoding SETD2 truncated fragments were cloned into pGEX-2T expression vectors between BamHI and EcoRI sites. STAT1 and SETD2 truncation expression vectors were transformed into Rosetta E. coli strain, then induced with 0.5 mM isopropy-b-D-thiogalactoside (IPTG) (Sigma-Aldrich) at 20 C for 20 hr. The expressed STAT1 proteins were purified using a 5 mL Ni HiTrap Chelating High Performance column (GE Life Sciences) with an AKTAprime plus system (GE Life Sciences), and then dialysed and stored in TBS buffer (25 mM Tris-HCl, 0.15 M NaCl, pH 7.2) at À80 C. The SETD2 truncated proteins were generated as follows: T1 (1$402 amino acids (aa.) of human SETD2), T2 (451$1067 aa.), T3 (1061$1691 aa.), T3N (962$1345 aa.), T3C (1252$1691 aa.), T4N (1469-1724 aa.), T4C (1704$2076 aa.), T4 (1389$2021 aa.), T5 (1940$2284 aa.) and T6 (2084$2564 aa.) truncated fragments tagged with GST were transformed into Rosetta E. coli strain and induced with 0.5 mM IPTG. Cells were collected and lysed in a high pressure cell disruptor (Constant Systems), and the expressed proteins were purified using the GST Spin Purification Kit (Pierce) following the manufacturer's instruction. In brief, protein extracts were incubated with resin bed containing Glutathione agarose, washed with Tris buffer (125 mM Tris, 150 mM sodium chloride, pH 8.0) five times, and GST-tagged proteins were eluted from the resin with Elution Buffer (3 mg/ml Glutathione in 125 mM Tris, 150 mM sodium chloride buffer.)
Histone proteins were extracted from 1 3 10 7 HepG2 cells following the histone extraction protocol available online (http://www.
abcam.com/protocols/histoneextraction-protocol-for-western-blot). Briefly, cells were lysed in Triton Extraction Buffer (TEB: PBS with 0.5% Triton X-100 (v/v) and protease inhibitor cocktail) on ice for 15 min. The pellet was then incubated in 0.2N HCl buffer overnight at 4 C, and the supernatant was collected after centrifugation.
GST Pull-down Assay GST pull-down assays were performed using GST Protein Interaction Pull-Down Kit (Pierce) following the manufacturer's instruction. In brief, 800 mg purified STAT1 protein was incubated with 100 mg of GST-tagged SETD2 truncated proteins or GST control protein in TBS buffer with glutathione agarose beads overnight at 4 C. The incubated proteins were then washed and immunoblotted using anti-STAT1 antibody.
In Vitro Methylation Assay 30 ng/ml purified SETD2 truncated fragment (1469-1724 aa.) and 30 ng/ml purified STAT1 or histone proteins were incubated in the reaction buffer with protease inhibitor cocktail (Merck) overnight at room temperature. The reaction buffer contained 50 mM Tris-HCl (pH 8.0), 2 mM MgCl 2 , 0.01% Trion X-100 (Takara), 1 mM Tris (2-CarboxyEthyl) Phosphine (TCEP) (Hampton Research) and 0.5 mM SAM (New England Biolabs) as the methyl group donor.
Immunofluorescence Paraffin-embedded sections of liver biopsies were performed as described (Liu et al., 2014b) . Briefly, liver biopsies were fixed, embedded into paraffin blocks, dewaxed, rehydrated, and microwaved. Sections were labeled with mouse anti-HBcAg (Abcam) and then FITC-conjugated to anti-mouse IgG antibody. The intracellular distributions of HBcAg were observed by confocal microscope and the Leica laser scanning software (TCS-SP2).
RNA-seq Analysis
Total RNA was isolated and used for RNA-seq analysis. cDNA library construction and sequencing were performed by Beijing Genomics Institute using BGISEQ-500 platform. High-quality reads were aligned to the human reference genome (GRCh38) using Bowtie2. The expression levels for each of the genes were normalized to fragments per kilobase of exon model per million mapped reads (FPKM) using RNA-seq by Expectation Maximization (RSEM).
Chromatin Immunoprecipitation (ChIP) Analysis ChIP analysis was performed as described (Zhang et al., 2015a) with H3K36me3 (ab9050) and the assay was performed according to manufacturer's instructions of the ChIP assay kit (Millipore). Fold enrichment was quantified using qRT-PCR and calculated as a percentage of input chromatin (% input).
QUANTIFICATION AND STATISTICAL ANALYSIS
The statistical significance of comparisons between two groups was analyzed with Student's t test. Differences were considered to be statistically significant when p values were less than 0.05.
DATA AND SOFTWARE AVAILABILITY
The RNA-seq data in this paper have been deposited in the Gene Expression Omnibus (GEO) with accession number GSE98372. 
